The University of Chicago Header Logo

Connection

David A. Ehrmann to Metformin

Back to Details
This is a "connection" page, showing publications David A. Ehrmann has written about Metformin.
David A. Ehrmann
Connection Strength
1.741
Metformin
  1. Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome. Diabetologia. 2017 09; 60(9):1656-1661.
    View in: PubMed
    Score: 0.538
  2. Weight loss and ß-cell responses following gastric banding or pharmacotherapy in adults with impaired glucose tolerance or type 2 diabetes: a randomized trial. Obesity (Silver Spring). 2022 08; 30(8):1579-1588.
    View in: PubMed
    Score: 0.190
  3. Effect of Metformin and Lifestyle Interventions on Mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care. 2021 12; 44(12):2775-2782.
    View in: PubMed
    Score: 0.180
  4. Withdrawal of medications leads to worsening of OGTT parameters in youth with impaired glucose tolerance or recently-diagnosed type 2 diabetes. Pediatr Diabetes. 2020 12; 21(8):1437-1446.
    View in: PubMed
    Score: 0.168
  5. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997 Feb; 82(2):524-30.
    View in: PubMed
    Score: 0.130
  6. Lifestyle and Metformin Ameliorate Insulin Sensitivity Independently of the Genetic Burden of Established Insulin Resistance Variants in Diabetes Prevention Program Participants. Diabetes. 2016 Feb; 65(2):520-6.
    View in: PubMed
    Score: 0.119
  7. Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2013 Dec; 98(12):4646-54.
    View in: PubMed
    Score: 0.103
  8. Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program. Diabetes. 2007 Apr; 56(4):1153-9.
    View in: PubMed
    Score: 0.066
  9. Pharmacologic therapy of polycystic ovary syndrome. Clin Obstet Gynecol. 2007 Mar; 50(1):244-54.
    View in: PubMed
    Score: 0.065
  10. Polycystic ovary syndrome. N Engl J Med. 2005 Mar 24; 352(12):1223-36.
    View in: PubMed
    Score: 0.057
  11. Insulin-lowering therapeutic modalities for polycystic ovary syndrome. Endocrinol Metab Clin North Am. 1999 Jun; 28(2):423-38, viii.
    View in: PubMed
    Score: 0.038
  12. Attenuation of hyperinsulinemia in polycystic ovary syndrome: what are the options? J Endocrinol Invest. 1998 Oct; 21(9):632-5.
    View in: PubMed
    Score: 0.036
  13. Variation in Maturity-Onset Diabetes of the Young Genes Influence Response to Interventions for Diabetes Prevention. J Clin Endocrinol Metab. 2017 08 01; 102(8):2678-2689.
    View in: PubMed
    Score: 0.034
  14. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes. 2005 Apr; 54(4):1150-6.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.